Bumper Offer - Urjas oil Just @ Rs. 1
Dalacin C 300 Capsule is a prescription drug, available for use as Capsule. It is typically used for the treatment of Bacterial Infections, Skin Infections. Secondary and off-label uses of Dalacin C 300 Capsule have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of Dalacin C 300 Capsule. Individual symptoms and route of administration also determines the right dosage. Refer to the dosage section for a detailed discussion.
Apart from the aforementioned side effects, Dalacin C 300 Capsule can also lead to other problems, which have been listed below. Such side effects of Dalacin C 300 Capsule normally do not last long and go away once the treatment is completed. However, if these continue for a longer time, consult your doctor right away.
Dalacin C 300 Capsule's effect during pregnancy is Severe and Moderate while nursing. It is important to know if Dalacin C 300 Capsule has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Dalacin C 300 Capsule related warnings section.
Other conditions have been mentioned below in the Dalacin C 300 Capsule contraindications section.
Additionally, Dalacin C 300 Capsule may also adversely react with other medicines. A complete list of these interactions is given below.
In addition to these precautions, you may also note that Dalacin C 300 Capsule is safe while driving, and is is addictive in nature.
Dalacin C 300 Capsule is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Dalacin C 300 Capsule is used -
Mild
Is the use of Dalacin C 300 Capsule safe for pregnant women?
Dalacin C should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Dalacin C 300 Capsule safe during breastfeeding?
Breastfeeding women may feel side effects of Dalacin C. If you see any side effects, stop taking Dalacin C immediately and talk to your doctor. Take Dalacin C again, only after your doctor's advice.
What is the effect of Dalacin C 300 Capsule on the Kidneys?
Dalacin C rarely harms the kidneys.
What is the effect of Dalacin C 300 Capsule on the Liver?
Side effects of Dalacin C rarely affect the liver.
What is the effect of Dalacin C 300 Capsule on the Heart?
Dalacin C is completely safe for the heart.
Dalacin C 300 Capsule should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Dalacin C 300 Capsule unless your doctor advises you to do so -
Is this Dalacin C 300 Capsule habit forming or addictive?
No, you will not get addicted to Dalacin C 300 Capsule.
Is it safe to drive or operate heavy machinery when consuming?
Dalacin C 300 Capsule does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Dalacin C 300 Capsule should be used only after doctor's advice.
Is it able to treat mental disorders?
Dalacin C 300 Capsule is unable to treat or cure mental disorders.
Interaction between Food and Dalacin C 300 Capsule
Taking Dalacin C 300 Capsule with food does not harm your health.
Interaction between Alcohol and Dalacin C 300 Capsule
It is difficult to say anything about the effect of Dalacin C 300 Capsule and alcohol. No research has been done on this yet.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; CLeocin HCl® clindamycin hydrochloride
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 756-757
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 328-330
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; CLeocin HCl® clindamycin hydrochloride
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 756-757
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 328-330
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; CLeocin HCl® clindamycin hydrochloride
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 756-757
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 328-330
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; CLeocin HCl® clindamycin hydrochloride
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 756-757
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 328-330
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; CLeocin HCl® clindamycin hydrochloride
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 756-757
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 328-330
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; CLeocin HCl® clindamycin hydrochloride
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 756-757
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 328-330
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 906
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Calcium Disodium Versenate (edetate calcium disodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 906
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Calcium Disodium Versenate (edetate calcium disodium)
